Geron | GERN - Cash And Equivalent

Stock Price
1.29
Daily Change
-0.11 -7.86%
Monthly
-23.67%
Yearly
1.57%
Q2 Forecast
1.26

Geron reported $68.9M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Amgen USD 12.04B 2.91B Mar/2026
Bio Techne USD 209.82M 36.94M Mar/2026
Cassava Sciences USD 86.57M 8.93M Mar/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
Exelixis USD 226.15M 256.34M Mar/2026
Genmab DKK 1.72B 46M Dec/2025
Geron USD 68.9M 10.54M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
Incyte USD 4.02B 435.22M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Novavax USD 228.36M 12.27M Mar/2026